Pemigatinib and Enfortumab Vedotin Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new treatment regimens for cancer that utilize FGFR inhibitors in combination with additional therapeutic agents, as current treatments are inadequate in addressing aberrant FGFR activity in various cancer types.
Innovation Solution
The administration of pemigatinib, an FGFR inhibitor, in combination with enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4, to treat cancer, with the option of simultaneous or sequential administration and varying dosages to achieve synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then treatment is simpler, but they are inadequate in addressing aberrant FGFR activity
Solution Approach 1:
The patent combines pemigatinib (an FGFR inhibitor) with enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) into a single treatment regimen. This merging of two different therapeutic mechanisms addresses the inadequacy of conventional single-agent therapies while managing complexity through coordinated administration protocols
2Reliability
If FGFR inhibitors are used alone, then the treatment regimen is simpler, but synergistic effects are not achieved
Solution Approach 1:
The patent merges pemigatinib and enfortumab vedotin into a combination therapy that achieves synergistic anti-tumor effects. The coordinated administration of these two agents with different mechanisms of action produces greater treatment outcomes than either agent alone, while the patent provides guidance on managing the complexity through defined dosing schedules and administration protocols
Data Source
AI summary
The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.